For research use only
| Cat No. | ABC-TC0117 |
| Product Type | Human Pancreas Cancer Cell Lines |
| Species | Human |
| Growth Conditions | 37 ℃, 5% CO2 |
| Source Organ | Pancreas |
| Product Code | CaPan-2; CAPAN-2; Capan 2; CAPAN 2; Capan2; CAPAN2 |
The cells produce high levels of MUC-1 mucin mRNA, low levels of MUC-2 mRNA but do not express the MUC-3 gene.
Capan-2 is a human pancreatic ductal adenocarcinoma cell line derived from a liver metastasis of a 56-year-old Caucasian male patient diagnosed with pancreatic cancer. These cells exhibit an epithelial morphology with cobblestone-like arrangements and grow as adherent monolayers in vitro. Capan-2 retains the ability to form tight junctions and polarized structures, expressing functional E-cadherin and forming dome-like colonies in culture. Karyotypic analysis revealed hypotriploid characteristics with multiple chromosomal aberrations. Importantly, Capan-2 cells express wild-type KRAS but harbor mutations in TP53 and SMAD4, which are frequently altered in pancreatic tumors. This cell line is moderately tumorigenic in immunodeficient mice and is often used in xenograft studies. The cells undergo rigorous screening and isolation procedures, and are rigorously tested to ensure they are free of contamination from HIV-1, HBV, HCV, Syphilis, Mycoplasma, Fungi, Yeast, and Bacteria.
| Product Code | CaPan-2; CAPAN-2; Capan 2; CAPAN 2; Capan2; CAPAN2 |
| Species | Human |
| Cat.No | ABC-TC0117 |
| Product Category | Tumor Cell Lines |
| Size/Quantity | 1 vial |
| Growth Mode | Adherent |
| Shipping Info | Dry Ice |
| Growth Conditions | 37 ℃, 5% CO2 |
| Source Organ | Pancreas |
| Biosafety Level | 1 |
| Storage | Liquid Nitrogen |
| Product Type | Human Pancreas Cancer Cell Lines |
Capan-2 is widely used to study pancreatic ductal adenocarcinoma biology, epithelial differentiation, and drug response. Its functional E-cadherin expression and ability to form polarized monolayers make it a valuable model for analyzing cell adhesion, invasion, and TGF-β-related signaling pathways. It also serves in preclinical evaluations of chemotherapeutic agents and targeted therapies, including EGFR and SMAD pathway modulators.
When you publish your research, please cite our product as “AcceGen Biotech Cat.# XXX-0000”. In return, we’ll give you a $200 coupon. Simply click here and submit your paper’s PubMed ID (PMID).
